DK3098309T3 - Rationelt designet enkeltkædet meganuclease med ikke-palindrome genkendelsessekvenser - Google Patents

Rationelt designet enkeltkædet meganuclease med ikke-palindrome genkendelsessekvenser Download PDF

Info

Publication number
DK3098309T3
DK3098309T3 DK16163925.7T DK16163925T DK3098309T3 DK 3098309 T3 DK3098309 T3 DK 3098309T3 DK 16163925 T DK16163925 T DK 16163925T DK 3098309 T3 DK3098309 T3 DK 3098309T3
Authority
DK
Denmark
Prior art keywords
single chain
recognition sequences
rationally designed
chain meganuclease
designed single
Prior art date
Application number
DK16163925.7T
Other languages
Danish (da)
English (en)
Inventor
James Jefferson Smith
Derek Jantz
Original Assignee
Prec Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prec Biosciences Inc filed Critical Prec Biosciences Inc
Application granted granted Critical
Publication of DK3098309T3 publication Critical patent/DK3098309T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/80Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/04Phosphoric diester hydrolases (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
DK16163925.7T 2007-10-31 2008-10-31 Rationelt designet enkeltkædet meganuclease med ikke-palindrome genkendelsessekvenser DK3098309T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US124707P 2007-10-31 2007-10-31
EP13165733.0A EP2660317B1 (en) 2007-10-31 2008-10-31 Rationally-designed single-chain meganucleases with non-palindromic recognition sequences

Publications (1)

Publication Number Publication Date
DK3098309T3 true DK3098309T3 (da) 2019-07-15

Family

ID=40591777

Family Applications (3)

Application Number Title Priority Date Filing Date
DK13165733.0T DK2660317T3 (en) 2007-10-31 2008-10-31 Rationally designed single-chain meganucleases with non-palindromic recognition sequences
DK08845549.8T DK2215223T3 (da) 2007-10-31 2008-10-31 Rationelt konstruerede enkeltkæde-meganucleaser med ikke-palindrome genkendelsessekvenser
DK16163925.7T DK3098309T3 (da) 2007-10-31 2008-10-31 Rationelt designet enkeltkædet meganuclease med ikke-palindrome genkendelsessekvenser

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK13165733.0T DK2660317T3 (en) 2007-10-31 2008-10-31 Rationally designed single-chain meganucleases with non-palindromic recognition sequences
DK08845549.8T DK2215223T3 (da) 2007-10-31 2008-10-31 Rationelt konstruerede enkeltkæde-meganucleaser med ikke-palindrome genkendelsessekvenser

Country Status (8)

Country Link
US (10) US8445251B2 (enExample)
EP (4) EP2215223B1 (enExample)
JP (7) JP5761996B2 (enExample)
AU (1) AU2008318430A1 (enExample)
CA (1) CA2704383A1 (enExample)
DK (3) DK2660317T3 (enExample)
ES (3) ES2732735T3 (enExample)
WO (1) WO2009059195A2 (enExample)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078619A1 (en) 2002-03-15 2003-09-25 Cellectis Hybrid and single chain meganucleases and use thereof
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
WO2009059195A2 (en) 2007-10-31 2009-05-07 Precision Biosciences Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
CA2782014C (en) 2009-11-27 2021-08-31 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
CA2781693C (en) 2009-11-27 2018-12-18 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
BR112012012444A2 (pt) 2009-11-27 2015-09-22 Basf Plant Science Co Gmbh "endonuclease quimérica, polinucleotídeo isolado, cassete de expressão, vetor, organismo não humano, método para fornecer uma endonuclease quimérica, método para recombinação homóloga de polinucleotídeos, método para mutação alvejada de polinucleotídeosa e método para recombinação homóloga ou mutação alvejada"
CA2794037A1 (en) 2010-03-22 2011-09-29 Philip Morris Products S.A. Modifying enzyme activity in plants
WO2012138901A1 (en) * 2011-04-05 2012-10-11 Cellectis Sa Method for enhancing rare-cutting endonuclease efficiency and uses thereof
EP3683319A1 (en) 2011-06-01 2020-07-22 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
EP2612918A1 (en) 2012-01-06 2013-07-10 BASF Plant Science Company GmbH In planta recombination
CA2872096A1 (en) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
ES3037550T3 (en) 2014-03-12 2025-10-03 Prec Biosciences Inc Dystrophin gene exon deletion using engineered nucleases
EP3189147A1 (en) 2014-09-07 2017-07-12 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
DK3289076T3 (da) 2015-05-01 2022-01-17 Prec Biosciences Inc Præcis sletning af kromosomale sekvenser in vivo
EP4292664A3 (en) 2015-05-15 2024-06-12 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
ES2920477T3 (es) 2015-06-19 2022-08-04 Prec Biosciences Inc Vectores virales autolimitantes que codifican nucleasas
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
US10882894B2 (en) 2015-08-11 2021-01-05 Anie Philip Peptidic TGF-beta antagonists
CA2997909A1 (en) 2015-09-08 2017-03-16 Precision Biosciences, Inc. Treatment of retinitis pigmentosa using engineered meganucleases
CN108601821B (zh) 2015-10-05 2023-09-19 精密生物科学公司 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
ES2883116T3 (es) 2015-10-05 2021-12-07 Prec Biosciences Inc Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
ES2901000T3 (es) 2015-12-23 2022-03-21 Prec Biosciences Inc Meganucleasas de ingeniería con secuencias de reconocimiento encontradas en el gen de la microglobulina beta-2 humana
US11274288B2 (en) 2016-02-16 2022-03-15 Emendobio Inc. Compositions and methods for promoting homology directed repair mediated gene editing
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2017189893A1 (en) 2016-04-27 2017-11-02 University Of Puerto Rico 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases
CA3022801A1 (en) 2016-05-03 2017-11-09 Precision Biosciences, Inc. Engineered nucleases useful for treatment of hemophilia a
WO2017223129A1 (en) 2016-06-22 2017-12-28 North Carolina State University Method for increasing nitrogen-use efficiency and or nitrogen-utilisation efficiency in plants
EP3487994A4 (en) * 2016-07-25 2020-01-29 Bluebird Bio, Inc. HOMING BCL11A ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
MA46059A (fr) 2016-08-23 2019-07-03 Bluebird Bio Inc Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation
KR102622910B1 (ko) 2016-09-08 2024-01-10 2세븐티 바이오, 인코포레이티드 Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법
JP6887492B6 (ja) 2016-10-04 2021-07-14 プレシジョン バイオサイエンシズ,インク. 遺伝子改変細胞で使用するための共刺激ドメイン
CN117402852A (zh) 2016-10-14 2024-01-16 精密生物科学公司 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶
WO2018075541A1 (en) * 2016-10-17 2018-04-26 Bluebird Bio, Inc. TGFβR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
EP3609890B1 (en) 2017-04-12 2024-09-11 EdiGene Biotechnology, Inc. Aryl hydrocarbon receptor antagonists and uses thereof
KR20230170125A (ko) * 2017-04-21 2023-12-18 프리시젼 바이오사이언시스 인코포레이티드 Pcsk9 유전자 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
US20200190541A1 (en) 2017-04-28 2020-06-18 Precision Biosciences, Inc. Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells
WO2018208837A1 (en) 2017-05-08 2018-11-15 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
CN110799644A (zh) 2017-05-25 2020-02-14 蓝鸟生物公司 Cblb核酸内切酶变体、组合物及使用方法
WO2018237107A1 (en) 2017-06-23 2018-12-27 University Of Kentucky Research Foundation Method
EP3645038A1 (en) 2017-06-30 2020-05-06 Precision Biosciences, Inc. Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
EP3661354A1 (en) 2017-07-31 2020-06-10 R. J. Reynolds Tobacco Company Methods and compositions for viral-based gene editing in plants
EP4269560A3 (en) 2017-10-03 2024-01-17 Precision Biosciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
WO2019070974A1 (en) * 2017-10-04 2019-04-11 Bluebird Bio, Inc. PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
US20190142974A1 (en) 2017-10-13 2019-05-16 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20190314407A1 (en) 2017-10-31 2019-10-17 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
CA3079404A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
WO2019089913A1 (en) 2017-11-01 2019-05-09 Precision Biosciences, Inc. Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
JP2021505172A (ja) 2017-12-06 2021-02-18 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 造血幹細胞及び前駆細胞を動員させるための投薬レジメン
WO2019126555A1 (en) * 2017-12-20 2019-06-27 Bluebird Bio, Inc. Ctla4 homing endonuclease variants, compositions, and methods of use
CN111902411A (zh) 2018-01-03 2020-11-06 美真达治疗公司 用于扩增造血干细胞和祖细胞以及治疗遗传性代谢紊乱的组合物和方法
UA128937C2 (uk) 2018-01-09 2024-12-04 Сайбас Юес Ллс Рослина brassica napus, що має знижену сприйнятливість до розстріскування плодів до збирання урожаю, та спосіб її одержання
EP3758682A4 (en) 2018-02-26 2021-12-15 Antolrx, Inc. TOLEROGENIC LIPOSOMES AND THEIR PROCEDURES FOR USE
CA3095047A1 (en) 2018-04-04 2019-10-10 Cibus Us Llc Fad2 genes and mutations
IT201800004253A1 (it) 2018-04-05 2019-10-05 Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria.
AU2019252527B2 (en) 2018-04-12 2024-02-22 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
EP3784790A4 (en) * 2018-04-27 2022-02-09 Seattle Children's Hospital d/b/a Seattle Children's Research Institute BRUTON TYROSINE KINASE HOMING ENDONUCLEAR VARIANTS, COMPOSITIONS AND METHOD OF USE
AU2019287720B2 (en) 2018-06-14 2025-08-28 Regeneron Pharmaceuticals, Inc. CD79A chimeric antigen receptors
GB201812603D0 (en) 2018-08-02 2018-09-19 British American Tobacco Investments Ltd Method
CA3111392A1 (en) 2018-09-04 2020-03-12 Magenta Therapeutics, Inc. Aryl hydrocarbon receptor antagonists and methods of use
WO2020072059A1 (en) 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
GB201817971D0 (en) 2018-11-02 2018-12-19 British American Tobacco Investments Ltd Method
GB201818715D0 (en) 2018-11-16 2019-01-02 British American Tobacco Investments Ltd Method
US12404500B2 (en) 2018-12-10 2025-09-02 Novo Nordisk A/S Homing endonuclease variants
US20220090047A1 (en) 2018-12-21 2022-03-24 Precision Biosciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
GB201900940D0 (en) 2019-01-23 2019-03-13 British American Tobacco Investments Ltd Method
KR102691932B1 (ko) 2019-04-03 2024-08-06 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
WO2020206231A1 (en) 2019-04-05 2020-10-08 Precision Biosciences, Inc. Methods of preparing populations of genetically-modified immune cells
CN120843482A (zh) 2019-05-07 2025-10-28 精密生物科学公司 用于识别序列的工程化大范围核酸酶的优化
GB201906768D0 (en) 2019-05-14 2019-06-26 British American Tobacco Investments Ltd Method
MX2021014566A (es) 2019-05-28 2022-03-22 Selecta Biosciences Inc Métodos y composiciones para la respuesta inmune atenuada anti-vector de transferencia viral.
GB201909563D0 (en) 2019-07-03 2019-08-14 British American Tobacco Investments Ltd Method
GB201909562D0 (en) 2019-07-03 2019-08-14 British American Tobacco Investments Ltd Method
CA3148179A1 (en) 2019-08-20 2021-02-25 Bruce J. Mccreedy Jr. Lymphodepletion dosing regimens for cellular immunotherapies
WO2021087305A1 (en) 2019-10-30 2021-05-06 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
WO2021087406A1 (en) 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
EP3835309A1 (en) 2019-12-13 2021-06-16 KWS SAAT SE & Co. KGaA Method for increasing cold or frost tolerance in a plant
WO2021158915A1 (en) 2020-02-06 2021-08-12 Precision Biosciences, Inc. Recombinant adeno-associated virus compositions and methods for producing and using the same
JP2023521055A (ja) 2020-04-09 2023-05-23 アール・ジエイ・レイノルズ・タバコ・カンパニー ニコチアナ・タバカムにおけるニコチンレベルの調整方法
AU2021263754A1 (en) 2020-04-27 2022-12-01 Ensoma, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
US20230183664A1 (en) 2020-05-11 2023-06-15 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
IL298138A (en) 2020-05-12 2023-01-01 Univ Pennsylvania Compositions for drg-specific reduction of transgene expression
WO2021231495A1 (en) 2020-05-12 2021-11-18 Precision Biosciences, Inc. Treatment of retinitis pigmentosa using improved engineered meganucleases
WO2022035793A1 (en) 2020-08-10 2022-02-17 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
WO2022040582A1 (en) 2020-08-21 2022-02-24 Precision Biosciences, Inc. Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene
US20230365995A1 (en) 2020-10-07 2023-11-16 Precision Biosciences, Inc. Lipid nanoparticle compositions
AU2021369793A1 (en) 2020-10-29 2023-06-08 The Trustees Of The University Of Pennsylvania Aav capsids and compositions containing same
WO2022104062A1 (en) 2020-11-12 2022-05-19 Precision Biosciences, Inc. Engineered meganucleases having specificity for recognition sequences in the dystrophin gene
CA3172161A1 (en) 2021-01-08 2022-07-14 James Jefferson Smith Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene
EP4284823A1 (en) 2021-01-28 2023-12-06 Precision BioSciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
US20240141311A1 (en) 2021-04-22 2024-05-02 North Carolina State University Compositions and methods for generating male sterile plants
JP2024514939A (ja) 2021-04-22 2024-04-03 プレシジョン バイオサイエンシズ,インク. ヒトミトコンドリアゲノムを標的化する遺伝子操作メガヌクレアーゼ
JP2024517655A (ja) 2021-04-22 2024-04-23 プレシジョン バイオサイエンシズ,インク. ヒトのミトコンドリアゲノムを標的とする操作されたメガヌクレアーゼ
TW202309066A (zh) 2021-04-27 2023-03-01 賓州大學委員會 衍生自豬的腺相關病毒衣殼及其用途
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20240408235A1 (en) 2021-10-19 2024-12-12 Precision Biosciences, Inc. Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
US20250228973A1 (en) 2021-10-19 2025-07-17 Precision Biosciences, Inc. Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
WO2023087019A2 (en) 2021-11-15 2023-05-19 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
US20250137006A1 (en) 2022-02-03 2025-05-01 Nicoventures Trading Limited Method of modulating alkaloid content in tobacco plants
AU2023215810A1 (en) 2022-02-03 2024-08-15 Nicoventures Trading Limited Method of modulating alkaloid content in tobacco plants
AU2023215671A1 (en) 2022-02-04 2024-08-15 Nicoventures Trading Limited Method of modulating alkaloid content in tobacco plants
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
GB202205149D0 (en) 2022-04-07 2022-05-25 Nicoventures Trading Ltd Method
GB202205148D0 (en) 2022-04-07 2022-05-25 Nicoventures Trading Ltd Method
GB202205561D0 (en) 2022-04-14 2022-06-01 Nicoventures Trading Ltd Method
GB202205562D0 (en) 2022-04-14 2022-06-01 Nicoventures Trading Ltd Method
GB202206109D0 (en) 2022-04-27 2022-06-08 Nicoventures Trading Ltd Method
GB202206107D0 (en) 2022-04-27 2022-06-08 Nicoventures Trading Ltd Method
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2024015966A2 (en) 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
EP4587568A2 (en) 2022-09-16 2025-07-23 King's College London Compositions and methods for treating neurological diseases
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
AU2023392154A1 (en) 2022-12-14 2025-06-26 King's College London Compositions and methods for treating neurological diseases
EP4646223A1 (en) 2023-01-05 2025-11-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
GB202300905D0 (en) 2023-01-20 2023-03-08 Nicoventures Trading Ltd Method
WO2024161022A2 (en) 2023-02-03 2024-08-08 King's College London Compositions and methods for treating neurological diseases
TW202449160A (zh) 2023-02-06 2024-12-16 美商藍岩醫療公司 降解決定子(degron)融合蛋白及其生產及使用方法
AU2024229544A1 (en) 2023-03-02 2025-10-16 Alloy Therapeutics, Inc. Anti-cd22 antibodies and uses thereof
GB202303077D0 (en) 2023-03-02 2023-04-19 Univ Oslo Brassica plants with improved seed retention
WO2024216118A1 (en) 2023-04-14 2024-10-17 Precision Biosciences, Inc. Muscle-specific expression cassettes
WO2024216116A1 (en) 2023-04-14 2024-10-17 Precision Biosciences, Inc. Muscle-specific expression cassettes
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
WO2025046513A1 (en) 2023-08-29 2025-03-06 Inceptor Bio, Llc Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
WO2025083169A1 (en) 2023-10-17 2025-04-24 Tenpoint Therapeutics Limited Combination of a vegf inhibitor and a complement pathway inhibitor for treating ocular disorders
WO2025101946A1 (en) * 2023-11-08 2025-05-15 Precision Biosciences, Inc. Polypeptide linkers for use in engineered meganucleases
WO2025126153A2 (en) 2023-12-14 2025-06-19 Aviadobio Ltd. Compositions and methods for treating sod1-mediated neurological diseases
WO2025233894A1 (en) 2024-05-09 2025-11-13 University Of Miami Engineered meganucleases that target human mitochondrial genomes
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US6156304A (en) 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US5997861A (en) 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
AU2002317771A1 (en) * 2001-06-05 2002-12-16 Cellectis Methods for modifying the cpg content of polynucleotides
US7241593B2 (en) * 2002-02-11 2007-07-10 Zymogenetics, Inc. Materials and methods for preparing dimeric growth factors
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
WO2003078619A1 (en) * 2002-03-15 2003-09-25 Cellectis Hybrid and single chain meganucleases and use thereof
CA2514417A1 (en) 2003-01-28 2004-08-12 Cellectis Custom-made meganuclease and use thereof
JP4095622B2 (ja) * 2004-03-31 2008-06-04 キヤノン株式会社 金結合性複合タンパク質
EP1591521A1 (en) * 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
WO2007034262A1 (en) 2005-09-19 2007-03-29 Cellectis Heterodimeric meganucleases and use thereof
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
EP1863909B2 (en) 2005-03-15 2014-09-10 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
EP1764414A1 (en) * 2005-09-17 2007-03-21 Icon Genetics AG Plant viral particles comprising a plurality of fusion proteins consisting of a plant viral coat protein, a peptide linker and a recombinant protein and use of such plant viral particles for protein purification
EP2628794B1 (en) * 2005-10-18 2016-05-04 Precision Biosciences Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2007049095A1 (en) 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
WO2007065098A2 (en) * 2005-11-29 2007-06-07 Virginia Commonwealth University Polyvalent chimeric ospc vaccinogen and diagnostic antigen
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
GB0603099D0 (en) * 2006-02-16 2006-03-29 Lontra Environmental Technolog Rotary piston and cylinder devices
WO2008010009A1 (en) 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
CA2669313A1 (en) 2006-11-14 2008-05-22 Cellectis Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof
WO2008059317A1 (en) 2006-11-14 2008-05-22 Cellectis Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof
WO2008093152A1 (en) 2007-02-01 2008-08-07 Cellectis Obligate heterodimer meganucleases and uses thereof
CN101679959A (zh) 2007-02-19 2010-03-24 赛莱克蒂斯公司 具有新的底物特异性的laglidadg归巢核酸内切酶变体及其用途
WO2008102199A1 (en) * 2007-02-20 2008-08-28 Cellectis Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof
WO2008149176A1 (en) * 2007-06-06 2008-12-11 Cellectis Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof
EP2167666A2 (en) 2007-06-29 2010-03-31 Pioneer Hi-Bred International Inc. Methods for altering the genome of a monocot plant cell
WO2009059195A2 (en) 2007-10-31 2009-05-07 Precision Biosciences Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
WO2009074842A1 (en) 2007-12-13 2009-06-18 Cellectis Improved chimeric meganuclease enzymes and uses thereof

Also Published As

Publication number Publication date
EP2215223A4 (en) 2011-01-05
US10041053B2 (en) 2018-08-07
WO2009059195A3 (en) 2009-09-03
ES2422291T3 (es) 2013-09-10
JP5761996B2 (ja) 2015-08-12
ES2575412T3 (es) 2016-06-28
EP3578646A2 (en) 2019-12-11
US9434931B2 (en) 2016-09-06
EP2215223A2 (en) 2010-08-11
EP2215223B1 (en) 2013-05-01
EP3098309B1 (en) 2019-04-10
EP3578646A3 (en) 2020-03-18
US20130267009A1 (en) 2013-10-10
EP3098309A1 (en) 2016-11-30
DK2215223T3 (da) 2013-07-22
JP2017051190A (ja) 2017-03-16
JP2011501971A (ja) 2011-01-20
US20150337335A1 (en) 2015-11-26
US8445251B2 (en) 2013-05-21
DK2660317T3 (en) 2016-08-01
EP2660317B1 (en) 2016-04-06
US20160002671A1 (en) 2016-01-07
JP2023029894A (ja) 2023-03-07
US9340777B2 (en) 2016-05-17
US20210054354A1 (en) 2021-02-25
EP2660317A1 (en) 2013-11-06
US20160002615A1 (en) 2016-01-07
JP6050861B2 (ja) 2016-12-21
US20100311817A1 (en) 2010-12-09
JP2019062898A (ja) 2019-04-25
JP2015221035A (ja) 2015-12-10
ES2732735T3 (es) 2019-11-25
US20160222417A1 (en) 2016-08-04
AU2008318430A1 (en) 2009-05-07
CA2704383A1 (en) 2009-05-07
JP2025028832A (ja) 2025-03-05
JP2021052770A (ja) 2021-04-08
US20180340160A1 (en) 2018-11-29
US20250154485A1 (en) 2025-05-15
US12351839B2 (en) 2025-07-08
US20230416711A1 (en) 2023-12-28
WO2009059195A2 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
DK3098309T3 (da) Rationelt designet enkeltkædet meganuclease med ikke-palindrome genkendelsessekvenser
BRPI0718796A2 (pt) Nucleotídeo
DE602007005217D1 (de) Fahrradkette
EP2132315A4 (en) REOVIRUS HAVING MODIFIED SEQUENCES
EP2209394A4 (en) Armtasche
DE502008000295D1 (de) Nockenwelle
DE602007004088D1 (de) Kettenförderer
DE502007002976D1 (de) Nockenwelle
ES2896053T8 (es) Biogel
FR2949750B1 (fr) Chaine de propulsion
EP2048992A4 (en) UTENSIL
EP2077854A4 (en) OMEGA-conotoxins
DE112008002937A5 (de) Geräuscharmer Kettentrieb
FIU20060412U0 (fi) Suojaliivi
AT508202A3 (de) Metallriemenkalander
AT504336B8 (de) Kettenrad
FI20060661A0 (fi) Kiinnike
DK2088872T3 (da) Overtrukne bærere
SE0601926L (sv) Kokkärl
DE502006007220D1 (de) Nockenwelle
DE112007003228A5 (de) Temperiervorrichtung
UA15228S (uk) Медальйон з ланцюжком
ES1066538Y (es) Llavero
FI20065600A0 (fi) Kampiakseli
ES1068660Y (es) Llavero